NVAX Q2 2021 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$298M+738.6% YoY

Gross Profit

$298M100.0% margin

Operating Income

-$346M-116.0% margin

Net Income

-$352M-118.2% margin

EPS (Diluted)

$-4.75

QoQ Revenue Growth

-33.4%

Cash Flow

Operating Cash Flow

$144M

Free Cash Flow

$129M

Stock-Based Comp.

$53M

Balance Sheet

Total Assets

$2.7B

Total Liabilities

$2.0B

Stockholders' Equity

$746M

Cash & Equivalents

$2.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$298M	$36M	+738.6%
Gross Profit	$298M	$36M	+738.6%
Operating Income	-$346M	-$17M	-1931.1%
Net Income	-$352M	-$18M	-1910.8%

Revenue Segments

Government Contract

$241M81%

Grant

$34M11%

Royalties and Other

$23M8%